SynAct Pharma AB (SYNACT.ST)
SynAct Pharma AB operates in the Biotechnology industry of the Healthcare sector, headquartered in Lund, SN, SE. The stock last traded at $17.30, down 0.92% on the session, giving a market capitalisation of $918.9M. Its beta of 0.76 implies it has historically moved less than the broad market.
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
SynAct Pharma AB is most often compared with the following Healthcare names: